There have been numerous documented successes, some of which we’ll look at in this article, and many reasons for continued optimism regarding positive growth trends in the local life sciences industries. According to recent data in Bio World Insight, collaborations between biotech and pharmaceutical companies for the first 11 months of 2013 exceeded $16 billion in a combination of public offerings and private transactions. The continued favorable outlook stems from the tangible economic growth of the U.S. financial markets, record high cash reserves and dividend increases of large pharma and biotech companies, a boost from the momentum of several, local successful exits in 2013 and a deep bench of strong companies with more accomplishments to follow. Learn More